Aethlon Medical, Inc. (AEMD): Price and Financial Metrics

Aethlon Medical, Inc. (AEMD): $1.71

0.01 (+0.39%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

AEMD Price/Volume Stats

Current price $1.71 52-week high $7.20
Prev. close $1.70 52-week low $1.40
Day low $1.61 Volume 4,300
Day high $1.80 Avg. volume 8,039
50-day MA $1.89 Dividend yield N/A
200-day MA $2.56 Market Cap 4.47M

AEMD Stock Price Chart Interactive Chart >

AEMD Stock Summary

  • AETHLON MEDICAL INC's market capitalization of $5,409,610 is ahead of just 2.81% of US-listed equities.
  • As for revenue growth, note that AEMD's revenue has grown 1,799.4% over the past 12 months; that beats the revenue growth of 99.6% of US companies in our set.
  • The volatility of AETHLON MEDICAL INC's share price is greater than that of 97.57% US stocks with at least 200 days of trading history.
  • Stocks that are quantitatively similar to AEMD, based on their financial statements, market capitalization, and price volatility, are GEVO, SAFE, FATH, NE, and CNX.
  • AEMD's SEC filings can be seen here. And to visit AETHLON MEDICAL INC's official web site, go to www.aethlonmedical.com.

AEMD Valuation Summary

  • AEMD's EV/EBIT ratio is 0.3; this is 97.95% lower than that of the median Healthcare stock.
  • AEMD's EV/EBIT ratio has moved up 10.9 over the prior 103 months.

Below are key valuation metrics over time for AEMD.

Stock Date P/S P/B P/E EV/EBIT
AEMD 2023-12-29 9.6 0.5 -0.5 0.3
AEMD 2023-12-28 9.4 0.5 -0.5 0.4
AEMD 2023-12-27 9.1 0.5 -0.4 0.4
AEMD 2023-12-26 8.4 0.5 -0.4 0.4
AEMD 2023-12-22 8.2 0.5 -0.4 0.4
AEMD 2023-12-21 8.2 0.5 -0.4 0.4

AEMD Growth Metrics

    Its 4 year price growth rate is now at -93.28%.
  • The year over year net cashflow from operations growth rate now stands at -44.38%.
  • Its 2 year net income to common stockholders growth rate is now at -63.42%.
Over the past 70 months, AEMD's revenue has gone down $378,957.

The table below shows AEMD's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 0.013116 -10.65749 -13.34793
2022-09-30 0.030233 -11.42449 -13.02391
2022-06-30 0.162199 -10.42425 -11.22446
2022-03-31 0.294165 -9.767157 -10.41609
2021-12-31 0.315282 -8.90671 -8.893984
2021-09-30 0.923036 -8.386 -8.811144

AEMD's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AEMD has a Quality Grade of D, ranking ahead of 11.25% of graded US stocks.
  • AEMD's asset turnover comes in at 0.049 -- ranking 72nd of 75 Measuring and Control Equipment stocks.
  • FCUV, SYPR, and SENS are the stocks whose asset turnover ratios are most correlated with AEMD.

The table below shows AEMD's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.049 1 11.337
2021-03-31 0.048 1 10.363
2020-12-31 0.061 1 11.087
2020-09-30 0.053 1 11.287
2020-06-30 0.076 1 13.238
2020-03-31 0.135 1 15.993

AEMD Price Target

For more insight on analysts targets of AEMD, see our AEMD price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.33 Average Broker Recommendation 1.5 (Moderate Buy)

Aethlon Medical, Inc. (AEMD) Company Bio


Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company is developing Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes exosomes and life-threatening viruses from the human circulatory system. It is also developing TauSome, an exosomal biomarker candidate to diagnose chronic traumatic encephalopathy in living individuals. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh for studies related to head and neck cancer. The company is based in San Diego, California.


AEMD Latest News Stream


Event/Time News Detail
Loading, please wait...

AEMD Latest Social Stream


Loading social stream, please wait...

View Full AEMD Social Stream

Latest AEMD News From Around the Web

Below are the latest news stories about AETHLON MEDICAL INC that investors may wish to consider to help them evaluate AEMD as an investment opportunity.

AEMD: Expect Focus on Oncology Studies; Cost Containment Efforts

By M. Marin NASDAQ:AEMD READ THE FULL AEMD RESEARCH REPORT Expect no disruption from management change; increased emphasis on studying Hemopurifier® in oncology likely… Aethlon Medical (NASDAQ:AEMD) appointed CFO James Frakes as interim CEO. We expect no disruption as a result of the management change – Mr. Frakes has been with Aethlon since 2008 & knows the company well, in our view.

Yahoo | November 16, 2023

Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript

Aethlon Medical, Inc. (NASDAQ:AEMD) Q2 2024 Earnings Call Transcript November 14, 2023 Operator: Good day, and welcome to the Aethlon Medical Second Quarter Fiscal 2024 Earnings and Corporate Update Call. [Operator Instructions]. Please note this event is being recorded. I would now like to turn the conference over to Mr. Michael Miller with Rx Communications. […]

Yahoo | November 16, 2023

Aethlon Medical Announces Fiscal Second Quarter Financial Results and Provides Corporate Update

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today reported financial results for its fiscal second quarter ended September 30, 2023 and provided an update on recent developments.

Yahoo | November 14, 2023

Aethlon Medical Announces Appointment of James B. Frakes, M.B.A. as Interim Chief Executive Officer and Guy Cipriani, M.B.A. as Chief Operating Officer

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that James B. Frakes, M.B.A., Chief Financial Officer of the Company, was appointed as Interim Chief Executive Officer, replacing Charles J. Fisher, Jr. M.D. Mr. Frakes also was appointed as a member of the Board of Directors and will remain as Chief Financial Officer of the Company. Additionally, Guy Cipriani, formerly Chief

Yahoo | November 13, 2023

Aethlon Medical to Release Second Quarter Financial Results and Host Conference Call on November 14, 2023

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening viral infections and for use in organ transplantation, today announced that it will issue financial results for its second quarter ended September 30, 2023, at 4:15 p.m. ET on Tuesday, November 14, 2023.

Yahoo | November 6, 2023

Read More 'AEMD' Stories Here

AEMD Price Returns

1-mo -10.47%
3-mo 1.47%
6-mo -43.00%
1-year -65.80%
3-year -92.88%
5-year -98.87%
YTD -21.92%
2023 -20.48%
2022 -85.19%
2021 -24.70%
2020 156.49%
2019 -96.13%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!